OBJECTIVE: The purpose of this study was to determine the symptoms that are experienced by patients who receive a diagnosis of early ovarian cancer and to compare those symptoms with the symptoms that are experienced by patients with late ovarian cancer, borderline ovarian cancer, and benign ovarian neoplasms. STUDY DESIGN: This study used a retrospective case-control design. Cases of invasive and borderline ovarian cancer (n=147 patients) were compared with 76 patients with benign ovarian neoplasms. RESULTS: Patients with early ovarian cancer were significantly more likely to have symptoms of mass effect (urinary frequency, constipation, palpable mass, pelvic pressure) compared with patients with benign ovarian neoplasms (67% vs 15%; P <.001), late stage disease (67% vs 40%; P =.008), and borderline cancer (67% vs 33%; P =.007). CONCLUSION: Mass effect symptoms were the only symptoms that differentiated patients with early-stage ovarian cancer from all other groups of patients. However, one third of the patients with early ovarian cancer did not report any of these symptoms.
OBJECTIVE: The purpose of this study was to determine the symptoms that are experienced by patients who receive a diagnosis of early ovarian cancer and to compare those symptoms with the symptoms that are experienced by patients with late ovarian cancer, borderline ovarian cancer, and benign ovarian neoplasms. STUDY DESIGN: This study used a retrospective case-control design. Cases of invasive and borderline ovarian cancer (n=147 patients) were compared with 76 patients with benign ovarian neoplasms. RESULTS:Patients with early ovarian cancer were significantly more likely to have symptoms of mass effect (urinary frequency, constipation, palpable mass, pelvic pressure) compared with patients with benign ovarian neoplasms (67% vs 15%; P <.001), late stage disease (67% vs 40%; P =.008), and borderline cancer (67% vs 33%; P =.007). CONCLUSION: Mass effect symptoms were the only symptoms that differentiated patients with early-stage ovarian cancer from all other groups of patients. However, one third of the patients with early ovarian cancer did not report any of these symptoms.
Authors: Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Rayna K Matsuno; Michael E Carney; Marc T Goodman Journal: Gynecol Oncol Date: 2010-06-29 Impact factor: 5.482
Authors: Thomas E Liggett; Anatoliy Melnikov; Qilong Yi; Charles Replogle; Wei Hu; Jacob Rotmensch; Aparna Kamat; Anil K Sood; Victor Levenson Journal: Gynecol Oncol Date: 2010-11-06 Impact factor: 5.482
Authors: Mary Anne Rossing; Kristine G Wicklund; Kara L Cushing-Haugen; Noel S Weiss Journal: J Natl Cancer Inst Date: 2010-01-28 Impact factor: 13.506
Authors: Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Marc T Goodman Journal: Gynecol Oncol Date: 2009-05-22 Impact factor: 5.482